Sanyou Bio achieves major breakthrough with monkeypox antibody launch

On August 28, 2024, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. unveiled a new range of 65 monkeypox-related products, which has garnered significant public acclaim. These products include antibodies, antigens, and cell lines, with the human monkeypox antibody standing out as a key offering due to its exceptional affinity activity and comprehensive data verification. This antibody is not only useful for developing therapeutic solutions but also for conducting structural analyses, research on bispecific antibodies, and creating diagnostic reagents and tools for scientific inquiry.

The newly introduced product lineup from Sanyou Bio consists of 65 distinct items, categorized into three main groups: 26 natural epitope antigens, 28 high-affinity, high-specificity monoclonal antibodies, and 11 overexpression cell lines. These products are designed to target multiple critical sites on the monkeypox virus's surface, including A29L, M1R, H3L, E8L, A35R, B6R, and key sites such as A28L, A30L, B21R, L1R, and I1L, which play crucial roles in the viral infection and assembly processes. All these products have undergone stringent data verification to ensure their reliability and efficacy.

Sanyou Bio leveraged its proprietary "over-trillion innovative antibody discovery" platform to develop these monoclonal antibodies. These antibodies encompass multiple species, including fully human, nano, and mouse antibodies, making them essential for therapeutic drug development. High-affinity nano antibodies, in particular, are highly valuable for structural analysis and bispecific research. Besides therapeutic applications, the full range of antibodies, natural epitope antigens, and overexpression cell lines can also be employed in the creation of diagnostic reagents and scientific research tools.

Through initiatives such as providing free trial kits of the full range of monkeypox virus antigens and antibodies, Sanyou Bio has facilitated global research efforts in various directions, including vaccines, drugs, and diagnostic reagents. This has accelerated the exploration and understanding of the monkeypox virus on a global scale.

Dr. Lang Guojun, CEO of Sanyou Biopharmaceuticals, highlighted the significant advancements made in monkeypox antibodies, particularly human monkeypox antibodies. He stated that Sanyou Bio aims to bolster the development of vaccines, therapeutics, diagnostic tools, and research initiatives, reinforcing its commitment to enhancing global public health.

Sanyou Biopharmaceuticals Co., Ltd. is a leading high-tech biotechnology firm dedicated to the research and development of innovative biologic drugs. The company employs a 4C business model that integrates differentiated CRO, integrated CDO, innovative CPO, and characteristic CRS, striving to simplify R&D processes for innovative biologics.

Sanyou Bio boasts a state-of-the-art innovative biologic drug R&D laboratory, equipped with advanced facilities and staffed by a highly qualified team, most of whom hold Ph.D. or master's degrees. The company has established three industry-leading technology platforms characterized by "super-trillion, integration, and intelligence," comprising over 50 sub-platforms. These platforms support various stages of biologics discovery and development, from material preparation and molecule optimization to upstream and downstream process development, preclinical R&D, and industrialization.

With a global business network, Sanyou Bio has expanded its presence across Asia, the US, and Europe, establishing branches in Boston, Philadelphia, San Diego, and London. The company has formed strong business relationships with over 1,000 pharmaceutical companies, drug R&D institutions, and diagnostics companies worldwide. Sanyou Bio has received national-level recognition as a high-tech enterprise and a Specialized and Sophisticated enterprise, along with ISO9001 quality assurance certification and GB/T intellectual property management system certification.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!